Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Physalis angulata* extract is a botanical substance derived from the Cutleaf Groundcherry plant, highly valued in dermatology for its concentration of **physalins**, which are naturally occurring secosteroids. It exhibits potent anti-inflammatory, antioxidant, and skin-soothing properties, often marketed as having a "corticosteroid-like" efficacy without the side effects associated with synthetic steroids, such as skin thinning or atrophy. The extract works by modulating the production of inflammatory mediators, specifically inhibiting the **NF-κB** signaling pathway and reducing the levels of pro-inflammatory cytokines like **TNF-α** and **IL-6**. It is primarily utilized in topical formulations to promote wound healing, accelerate re-epithelialization, and treat conditions characterized by erythema and skin sensitivity. It has been investigated in combination products (such as Ready Medical Post Treatment) to improve recovery after surgical procedures like split-thickness skin grafting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on physalis angulata extract.